Prognostic Significance Of RAAS Inhibition In Heart Failure Patients With Co-existing End Stage Renal Disease On Hemodialysis
Won-Joon Koh,Alaa M. Omar,Anna S. Mueller,Christopher N. Matthews,Joseph Marinelli,Justin Goodfarb,Mohammad I. Khan,Muhammad Ghallab,Sean Pinney,Ashish Correa,Kiran Mahmood,Arieh Fox
DOI: https://doi.org/10.1016/j.cardfail.2023.10.440
IF: 6.592
2024-01-01
Journal of Cardiac Failure
Abstract:Introduction Patients with end stage renal disease (ESRD) are largely excluded from clinical trials concerned with heart failure (HF) therapeutics, leading to a dearth of quality evidence of guideline directed medical therapy (GDMT) in this high-risk group. Furthermore, renin angiotensin aldosterone system inhibition (RAASi) is generally avoided in hemodialysis patients due to potential side effects including hypotension and hyperkalemia, possibly negating the known benefits of these medications. We studied the prognostic significance of RAASi in HF patients with ESRD on hemodialysis. Methods In a retrospective study protocol, we studied patients followed in our HF clinic who had concomitant ESRD on hemodialysis. Individual and combined RAASi use was registered, and baseline clinical, hemodynamic, and echocardiographic data were assessed. Patients were followed for a median of 31.8 months for cardiac mortality and HF hospitalizations. Results From 2014 to 2022, 89 patients were included for analysis [age: 62.4±15 years, 43% women, EF: 46±15%, 39 (45%) reduced EF (HFrEF), and 60 (55%) preserved EF (HFpEF)]. During follow-up, 14 (16%) patients died, and 61 (69%) patients had HF hospitalizations. 56 (63%) patients were on RAASi (ACEi, ARBs, ARNI), with no significant differences in baseline characteristics (e.g. age, sex, cause of cardiomyopathy, risk factors, device therapy, AHA/ACC class, BNP, baseline EF) (44.1±14.7 vs. 48.7±15, p=0.167) or follow-up EF (44.7±14 vs. 50±15.7, p=130) compared to those not on RAASi. Although RAASi patients had more hypotension (48% vs. 20%, p=0.014), RAASi-related adverse events (cough, angioedema, hyperkalemia, intradialytic hypotension, intradialytic inotrope) were similar between both groups. Compared to patients not on RAASi, RAASi patients had statistically significant increase in HF hospitalizations [44 (79%) vs. 17 (52%), p=0.004), but were associated with a trend towards fewer deaths [6(11%) vs. 8(24%), p=0.09]. Both HFrEF patients and HFpEF patients had comparable RAASi use (55% vs. 69%, p=0.162), and did not differ in outcomes of mortality (18% vs. 14%, p=0.679) and rehospitalization (73% vs. 65%, p=0.467). Moreover, on survival analysis, RAASi had significantly less risk for mortality (HR: 0.33, 95% CI 0.11 to 0.97, Figure 1A,C) but no differences in hospitalization (HR: 1.72, 95% CI: 0.98 to 3, Figure 1B,C). Similar results were obtained after adjusting for co-variates. Conclusions In our study, although hypotension was more common in patients receiving RAASi, hyperkalemia and intradialytic hypotension were not associated with RAASi use. If tolerated, RAASi was associated with improved mortality, but not hospitalization.
cardiac & cardiovascular systems